Morgan Stanley lowered the firm’s price target on Roche to CHF 280 from CHF 290 and keeps an Equal Weight rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RHHBY:
- Genentech announces FDA approval for Vabysmo
- [Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO)
- Roche announces collaboration with Ibex Medical Analytics, Amazon Web Services
- Immunovant price target raised to $57 from $28 at Piper Sandler
- Roivant (NASDAQ:ROIV) Gains after Roche’s $7.1 Billion Buy of Televant